Volume 5 Supplement 1

Abstracts from the 1st Clinical Research Informatics (CRI) Solutions Day 2014

Open Access

Mobile eHealth solution (ePRO)

  • Stanisław Saganowski1Email author,
  • Piotr Bródka1,
  • Andrzej Misiaszek1 and
  • Kazimierz Fraczkowski1
Journal of Clinical Bioinformatics20155(Suppl 1):S14

https://doi.org/10.1186/2043-9113-5-S1-S14

Published: 22 May 2015

Characterisation

ePRO (electronic Patient Reported Outcome), PROM (Patient Reported Outcome Measures), Android, iOS, TRANSFoRm, clinical trials.

Description

The mobile eHealth solution developed in the TRANSFoRm project is part of the TRANSFoRm platform to support the identification of prevalent and incident cases in the GORD clinical trial use case, including the randomization of patients for on-demand or continuous consumption of PPIs [1]. This TRANSFoRm Study System (TSS) consists of five major parts:

  • Study server – manages the connection between mobile and web applications and the TSS

  • Study database – stores all information about studies, patients, randomization etc.

  • Web application – enables filling in PROMs by patients and CROMs by GPs (investigators)

  • Mobile application – enables filling in PROMs by the patients using smartphones or other devices

  • Middleware - ESB which serves as a connection, authorization and security layer between TSS and the rest of the infrastructure

As part of this TRANSFoRm Study System data collection is done by web applications (eCRF) and mobile questionnaires (PROM). Patients report their data, for example data about their quality of life, by using mobile health applications from their homes. For this purpose, Android and iOS based applications communicate with the study server in order to authenticate a patient, retrieve a list of questionnaires to be filled out, and upload completed questionnaires. Communication between these components is done via secure SSL connections.

The mobile applications are capable of generating any questionnaire provided in the ODM standard format. After the patient has completed the questionnaire all data is packed into a XML file compatible with ODM and securely send to the server. No data remains on the mobile device, thereby providing additional protection of patient data. Applications offer several language versions; the proper one is selected based on the language chosen on the device. Recently the mobile eHealth solution is being evaluated by employing it in the GORD trial, a multicenter international randomized trial planning to recruit about 1000 patients with gastro-oesophageal reflux disease [1, 2].

Status of development

Development of the Transform Study System is completed. All components are in the testing phase and since December 2014 the validation phase is being conducted. The Android and iOS applications will be available free of charge on Google Play and App Store.

Users

Patients participating in a study, General Practitioners (GP), researchers.

Link

Authors’ Affiliations

(1)
Wroclaw University of Technology

References

  1. Andreasson AN, Verheij RA, Hek K: The effect of on demand versus continuous use of proton pump inhibitors on reflux symptoms, quality of life and self-rated health in patients with gastro-oesophageal reflux disease. Evaluation Study Research Ethics Protocol Protocol. 2014, ID KIANANDR140701 (draft)Google Scholar
  2. Mastellos N, Huckvale K, Larsen M, Car J, Andreasson AN, Agreus L: Protocol for evaluation studies for the GORD use case. Study protocol. 2014, (TRANSFoRm)Google Scholar

Copyright

© Saganowski et al; licensee BioMed Central Ltd. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement